Search Results for "Hydromorphone Hydrochloride Dosage"
Original Source: Hydromorphone Hydrochloride [PD-Rx Pharmaceuticals, Inc.]
HYDROMORPHONE HYDROCHLORIDE TABLETS USP, 2 mg, 4 mg, and 8 mg
Matching Channels
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to...
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles'...
Generics Drugs - news, views, reports
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration,...
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides...
Matching News
Opioid pain medications such as hydromorphone have life-threatening consequences if overdosed.
Hospira recalls overfilled hydromorphone hydrochloride vials
Hospira first alerted FDA in April and May 2012 of overfilled cartridges containing morphine and hydromorphone. Subsequent investigation by the company has revealed that as many as 280 batches of...
Mallinckrodt, Actavis enter settlement agreement to resolve Exalgo patent litigation
Actavis, Inc. today announced that it has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt'...
Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Hydromorphone Injection, USP, 2 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1312-30 ,...
Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR
US generics drug major Actavis (NYSE: ACT) has reached a settlement with Mallinckrodt (NYSE: MKG) on outstanding patent litigation related to Actavis' generic version of the 32mg dosage strength of Ma...
Carpuject Hydromorphone Prefilled Syringes Recalled
The FDA is reporting a recall of one lot of Hospira hydromorphone injection for use with Carpuject cartridges. Medscape Medical News
Hospira recalls Hydromorphone Injection at user level
Hospira has announced a nationwide voluntary recall of one lot of Hydromorphone Injection, USP, 2mg/mL (C-II), 1mL fill in 2.5mL Carpuject, NDC 0409-1312-30 , due to a reported complaint of a single C...
Hospira recalls hydromorphone pain product on overdose concerns
USA-based Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, last week initiated a voluntary user level recall of one lot of hydromorphone injection, due...
Matching PubMed Articles
A sensitive reverse phase high performance liquid chromatography-electrospray ionization-mass spectrometry (RP-HPLC-ESI-MS) method has been developed and validated for the determination of hydromorpho...
Objective-To determine the effects of IM administration of acepromazine, hydromorphone, or the acepromazine-hydromorphone combination on degree of sedation in clinically normal dogs and to compare 2 s...
Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form.
Objective: The objective of present investigation was to evaluate performance of cocrystals of Mefloquine Hydrochloride (MFL) in tablet dosage form. Our previous investigation showed significant effec...
Development and validation of a paediatric oral formulation of clonidine hydrochloride.
Many drugs are unavailable in suitable paediatric dosage forms. We describe the development and validation of a stable paediatric oral formulation of clonidine hydrochloride 50 μg/ml, allowing indivi...
Objective-To assess the efficacy of a retrobulbar bupivacaine nerve block for postoperative analgesia following eye enucleation in dogs. Design-Randomized controlled trial. Animals-22 dogs. Procedures...
